STOCK TITAN

Illumina Inc - ILMN STOCK NEWS

Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.

Overview of Illumina Inc.

Illumina Inc. (NASDAQ: ILMN) is a global leader in DNA sequencing and array-based technologies, revolutionizing the field of genomics through innovative tools and solutions. The company’s core mission is to unlock the power of the genome to improve human health, enabling transformative advancements in personalized medicine, disease research, drug discovery, and agricultural innovation. By providing cutting-edge sequencing instruments, consumables, and bioinformatics solutions, Illumina empowers researchers, clinicians, and organizations across diverse sectors to decode genetic information with unprecedented precision and scale.

Core Business Areas

Illumina’s business model is centered around the development and commercialization of high-throughput sequencing systems, consumables, and services that cater to a wide range of applications. The company’s offerings include:

  • Sequencing Instruments: Illumina’s flagship platforms, such as the NovaSeq™ series, deliver scalable, high-throughput sequencing capabilities that support whole-genome sequencing, transcriptomics, and multiomics.
  • Consumables: Proprietary reagents, flow cells, and sample preparation kits designed for seamless integration with Illumina’s sequencing systems.
  • Bioinformatics Solutions: Advanced software tools like DRAGEN™ enable rapid, accurate analysis of genomic data, streamlining workflows from raw data to actionable insights.
  • Array-Based Technologies: Microarrays for targeted genetic screening, serving applications in consumer genomics, agriculture, and clinical diagnostics.

Industry Applications

Illumina’s technologies are widely adopted across various industries, including:

  • Life Sciences Research: Supporting basic and applied research in genomics, transcriptomics, and epigenetics.
  • Oncology: Enabling comprehensive genomic profiling, biomarker discovery, and precision oncology research.
  • Reproductive Health: Advancing non-invasive prenatal testing (NIPT) and carrier screening.
  • Agriculture: Facilitating crop improvement and livestock breeding through genomic insights.
  • Population Genomics: Partnering with national initiatives to sequence diverse populations and drive precision medicine.

Competitive Position and Innovation

Illumina maintains its leadership in the genomics space through continuous innovation and a customer-centric approach. Its proprietary technologies, such as XLEAP-SBS™ chemistry and DRAGEN bioinformatics, set new benchmarks for accuracy, speed, and scalability in sequencing. The company’s commitment to end-to-end solutions, including sample preparation, sequencing, and data analysis, ensures a seamless user experience and accelerates scientific discovery.

Market Significance

Illumina’s impact extends beyond technology; it plays a pivotal role in advancing global health initiatives. From supporting population genomics programs to enabling breakthroughs in cancer research and rare disease diagnostics, Illumina’s contributions are shaping the future of healthcare and biotechnology. Its collaborations with academic institutions, clinical labs, and industry leaders further solidify its position as a trusted partner in the genomics ecosystem.

Conclusion

With its unwavering focus on innovation, scalability, and customer needs, Illumina continues to lead the way in genomics, empowering researchers and clinicians to harness the full potential of genetic information. Its comprehensive portfolio of products and services positions it as an indispensable player in the pursuit of improved health outcomes and scientific advancement.

Rhea-AI Summary
DataGene (Ticker: DG) introduces Sustainability Index for dairy cattle herds to combat methane emissions, a significant driver of global warming. The index aims to address the environmental impact of cattle farming by focusing on the genetic factors influencing methane emissions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.08%
Tags
none
-
Rhea-AI Summary
Illumina, Inc. (NASDAQ: ILMN) announced the divestiture of GRAIL, in compliance with the European Commission's order, aiming to finalize the terms by Q2 2024. The company will not pursue further appeals after the U.S. Fifth Circuit Court of Appeals decision. Jacob Thaysen, CEO, expressed confidence in Illumina's core business and long-term success.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Illumina (ILMN) has been named to the Dow Jones Sustainability World Index and the North America Index for 2023 in the Life Sciences Tools & Services Industry. This is the fifth consecutive year the company has been named to the prestigious list and the fourth year that it has led with the highest score in the Life Sciences Tools & Services Sector industry in North America. The Dow Jones Sustainability Index (DJSI) is based on the S&P Global Corporate Sustainability Assessment (CSA) annual evaluation of companies' sustainability practices. The DJSI represents the top 10% of each industry in the DJSI World Index and the top 20% for the DJSI North America Index. Illumina's commitment to deepening its impact on human health and sustainability is evident through this recognition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Illumina, Inc. (NASDAQ: ILMN) has submitted a draft registration statement on Form 10 for the potential divestiture of GRAIL to the U.S. Securities and Exchange Commission. The company received an order from the European Commission (EC) directing the divestiture of GRAIL. Illumina is exploring divestiture options to achieve maximum value for shareholders and the best outcome for GRAIL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.16%
Tags
none
-
Rhea-AI Summary
GRAIL, LLC (AZN) presented validation results for a plasma-based targeted methylation assay for early-stage lung cancer at the North America Conference on Lung Cancer 2023. The assay demonstrated the potential to identify high-risk patients who might benefit from additional treatment. The clinical validation studies showed that the presence of ctDNA correlated with an inferior two-year recurrence-free survival, and ctDNA positivity was associated with higher rates of mediastinal nodal upstaging at resection, PD-L1 positivity, and grade 3 histology. Analytical studies also demonstrated high analytical specificity, accuracy to detect signal at low ctDNA input, and a robust LoD95 of tumor methylated fraction. GRAIL has a strategic collaboration with AstraZeneca to develop and commercialize companion diagnostic assays for use with AstraZeneca’s therapies, and the company has announced the availability of its state-of-the-art research use only methylation solution for custom oncology applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
none
-
Rhea-AI Summary
Illumina (ILMN) is partnering with the Ontario Institute for Cancer Research (OICR) to push the boundaries of precision oncology. OICR aims to bring researchers, clinicians, and institutes together to solve cancer problems through precision medicine. The institute features a fully equipped genomic sequencing facility and is working to deliver clinically relevant data in a timely manner. OICR's partner organizations, such as Princess Margaret Cancer Centre, rely on genomic sequencing data to guide treatment and clinical trials. The collaboration with Illumina has led to faster genomic sequencing capabilities, potentially changing the economics of genomic sequencing and opening new applications for precision oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
Rhea-AI Summary
GRAIL, LLC: Announces the initiation of Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity (REACH/Galleri-Medicare study) following FDA and CMS approvals. The study aims to assess the clinical impact of Galleri® multi-cancer early detection test among Medicare beneficiaries, with a focus on under-represented groups. Medicare will cover the costs of Galleri and related items and services for study participants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
none
-
Rhea-AI Summary
Illumina, Inc. (NASDAQ: ILMN) executives to speak at investor conferences. Webcasts accessible through Investor Info section of Illumina's website. Replays available for at least 30 days after each event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
conferences
-
Rhea-AI Summary
Illumina Inc. (NASDAQ: ILMN) Launches Global Health Access Initiative to Address Barriers to Genomic Sequencing in Low- and Middle-Income Countries (LMICs)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.67%
Tags
none
Rhea-AI Summary
Illumina, Inc. (Nasdaq: ILMN) announced the appointment of new CEO Jacob Thaysen, Ph.D., and provided financial results for Q3 2023, including revenue of $1.12 billion, a flat year-over-year comparison. The company also expects a decrease in fiscal year 2023 revenue and diluted earnings per share. Illumina remains committed to divesting GRAIL and is focused on driving placements of the NovaSeq X instruments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.05%
Tags

FAQ

What is the current stock price of Illumina (ILMN)?

The current stock price of Illumina (ILMN) is $84.2 as of March 3, 2025.

What is the market cap of Illumina (ILMN)?

The market cap of Illumina (ILMN) is approximately 13.9B.

What does Illumina Inc. specialize in?

Illumina specializes in DNA sequencing and array-based technologies, providing tools and services for genetic analysis across research, clinical, and applied markets.

How does Illumina generate revenue?

Illumina generates revenue through the sale of sequencing instruments, consumables, and bioinformatics solutions, as well as providing related services.

What industries use Illumina’s technologies?

Illumina’s technologies are used in life sciences research, oncology, reproductive health, agriculture, and population genomics, among other fields.

What makes Illumina’s technology unique?

Illumina’s proprietary technologies, such as XLEAP-SBS chemistry and DRAGEN bioinformatics, offer unmatched accuracy, scalability, and efficiency in genomic sequencing and analysis.

How does Illumina support population genomics programs?

Illumina collaborates with national initiatives to sequence diverse populations, providing the tools and expertise needed to advance precision medicine and public health.

What are the key applications of Illumina’s sequencing platforms?

Key applications include whole-genome sequencing, transcriptomics, multiomics, biomarker discovery, and targeted genetic screening.

What role does Illumina play in precision medicine?

Illumina’s technologies enable the identification of genetic biomarkers and actionable mutations, supporting personalized treatment strategies in precision medicine.

What is Illumina’s approach to innovation?

Illumina focuses on developing end-to-end solutions that integrate sample preparation, sequencing, and data analysis, ensuring seamless workflows and accelerating discovery.
Illumina Inc

Nasdaq:ILMN

ILMN Rankings

ILMN Stock Data

13.91B
157.59M
0.27%
107.22%
3.76%
Diagnostics & Research
Laboratory Analytical Instruments
Link
United States
SAN DIEGO